Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of Sollpura versus Pancreaze in cystic fibrosis with exocrine pancreatic insufficiency
MOH_2017-06-15_000393Phase 3Not yet recruiting
- Sponsor
- Anthera Pharmaceuticals, Inc.
- Start
- May 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pancrelipase in exocrine pancreatic insufficiency (EPI) and cystic fibrosis (CF) (2 arms), sponsored by Anthera Pharmaceuticals, Inc. Primary endpoint: Change in coefficient of fat absorption. Planned start May 2017; status: not yet recruiting.
02
Drugs
pancrelipase
03
Conditions
exocrine pancreatic insufficiency (EPI)cystic fibrosis (CF)
Beyond the preview
Go deeper on MOH_2017-06-15_000393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-15_000393.